Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
[no abstract]
Saved in:
Main Authors: | Lim, Sun Min, Tan, Jiunn-Liang, Dias, Josiane Mourao, Voon, Pei Jye, How, Soon Hin, Zhou, Xiangdong, Xiong, Hailin, Massuti, Bartomeu, Medley, Louise C., Nagasaka, Misako, Vicente, David, Girard, Nicolas, Rittmeyer, Achim, Botesteanu, Dana-Adriana, Alhadab, Ali, Mahoney, Janine M., Zhang, Jie, Bauml, Joshua Michael, Baig, Mahadi, Scott, Susan Combs |
---|---|
Format: | Article |
Published: |
American Society of Clinical Oncology
2024
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/46894/ https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8612 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
by: Passaro, A., et al.
Published: (2024) -
Web 2.0. c'est à dire...
by: Girard, Helene
Published: (2011) -
Petite archéologie du Web 2.0
by: Girard, Helene
Published: (2011) -
Solar radiation estimation with neural network approach using meteorological data in Indonesia
by: Rumbayan, Meita, et al.
Published: (2011) -
Consumer buying behaviour of tourism product: a case study of travel agent in Wisma Sabah / Debs Girard Dos
by: Girard Dos, Debs
Published: (2010)